Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #4 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Senores Pharmaceuticals expects 30% to 40% top-line growth (revenue) for FY27, with INR100 crores contribution from the Apnar facility. Revenue growth guidance for FY27 is 30% to 40%, with a minimum achievable target set conservatively due to external uncertainties.
From Senores Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Senores Pharmaceuticals expects 30% to 40% top-line growth (revenue) for FY27, with INR100 crores contribution from the Apnar facility.
- Emerging markets revenue projected at around INR180 crores for FY27, with EBITDA margins potentially improving to 20%-21%.
- Apnar facility revenue anticipated to grow from INR10-20 crores quarterly in FY26 to INR80-100 crores annually in FY27, and INR180-200 crores in 2-3 years.
- US regulated business targeted to reach INR2,500 to INR3,000 crores in revenue within 3-4 years.
- The company plans to launch over 30 ANDAs in the near term, with many qualifying for first-to-launch CGT products for faster market access.
2 more points from Senores Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- INR100 crore of unutilized IPO funds planned for development of sterile manufacturing; utilization to begin within this year and continue over the next couple of years.
- Capex for FY27 is guided at around INR200 crore, including:
- INR100 crore allocated for injectable facility development.
- INR100 crore for various other plants and maintenance capex.
2 more points from Senores Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Senores Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Senores Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹192 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Senores Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Senores Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Senores Pharmaceuticals Ltd Q4 FY26 results?
Senores Pharmaceuticals expects 30% to 40% top-line growth (revenue) for FY27, with INR100 crores contribution from the Apnar facility. Revenue growth guidance for FY27 is 30% to 40%, with a minimum achievable target set conservatively due to external uncertainties.
What is Senores Pharmaceuticals Ltd share price analysis?
Senores Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.9 with a market cap of ₹6,805 Cr. Investors should review the full earnings analysis for detailed insights.
Is Senores Pharmaceuticals Ltd planning capital expenditure?
INR100 crore of unutilized IPO funds planned for development of sterile manufacturing; utilization to begin within this year and continue over the next couple of years.
Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.